Delivery Order SPE2DB20D3103-SPE2DB21FL7D5
- Not listed
- This federal contract award is for a prime vendor pharmaceutical supply contract held by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $1,108.29, was awarded by the Defense Logistics Agency (DLA) and is for the delivery of a broad range of pharmaceutical products, medical supplies, and equipment to support military and veterans' healthcare programs. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of April 16, 2021. The...
- This federal contract award is for a prime vendor pharmaceutical distribution contract held by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $1,517.76, was awarded by the Defense Logistics Agency (DLA) on November 20, 2020, with an ultimate completion date of November 23, 2020. The contract is for the delivery of a variety of pharmaceutical products, medical supplies, and equipment to support military treatment facilities, veterans' healthcare programs, and...
- This federal contract award is for pharmaceutical and medical supply distribution services provided by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $2,940.60 delivery order was issued by the Defense Logistics Agency (DLA) and has a firm fixed price. The contract supports the DLA Troop Support Medical program, providing a range of pharmaceutical products, medical devices, and other healthcare commodities to military treatment facilities and veterans' healthcare programs....
- This federal contract award is for a prime vendor pharmaceutical distribution contract to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $14,492.74 firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) for pharmaceutical products and medical supplies to support military treatment facilities and veterans' healthcare programs. The contract has an ultimate completion date of July 22, 2021. Amerisourcebergen Drug Corp holds a significant $999,999,999...
- This federal contract award is for a prime vendor pharmaceutical contract held by Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, awarded by the Defense Logistics Agency (DLA), is a delivery order valued at $3,338.48 for pharmaceutical products and medical supplies to support military and veteran healthcare programs. The contract has an ultimate completion date of December 31, 2020 and is a firm fixed price delivery order with no set-aside designation,...
- This federal contract award is for a prime vendor pharmaceutical delivery order to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $2,428.92 firm fixed-price contract was awarded by the Defense Logistics Agency (DLA) on July 12, 2021, with a completion date of July 13, 2021. The contract is for the delivery of a variety of pharmaceutical products, including specialty medications, brand-name drugs, generic pharmaceuticals, and medical supplies to support military treatment...
- This federal contract award is for a pharmaceutical prime vendor contract held by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $6,242.53, was awarded by the Defense Logistics Agency (DLA) for the delivery of pharmaceutical products and medical supplies to support military healthcare programs. The contract has an ultimate completion date of January 15, 2021 and is a firm fixed-price delivery order with no set-aside designation, indicating open competition....
- This federal contract award is for a prime vendor pharmaceutical distribution contract with the Defense Logistics Agency (DLA) awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at up to $2,286.30, is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC enables Amerisourcebergen to provide a comprehensive range of pharmaceutical...
- This federal contract award is for a prime vendor pharmaceutical contract from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $2,753.30 firm fixed-price delivery order supports the supply of a wide range of pharmaceutical products and medical supplies, including specialty medications, generic drugs, brand-name pharmaceuticals, medical devices, syringes, vials, and vaccines, to military treatment facilities, veterans' healthcare programs,...
- This federal contract award is for pharmaceutical and medical supply distribution services provided by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $1,738.78 contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical on a firm-fixed-price basis. The contract covers the delivery of a wide range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB21FL7D5Delivery Order
This federal contract award is for a prime vendor pharmaceutical supply contract held by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at $6,082.31, was awarded by the Defense Logistics Agency (DLA) to provide a wide range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The contract, which has an ultimate completion date of December 2, 2020, is a Firm Fixed Price Delivery Order and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026, which serves as the primary vehicle for the company to deliver comprehensive pharmaceutical and medical supplies to the Department of Defense globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.1k | 12/1/20 |